The quest to conquer age-related macular degeneration.
AMD causes irreversible blindness in the elderly. For years, treatment has been non-existent or ineffective. With the advent of anti-VEGF agents, ophthalmologists can stabilize and even improve visual function in these patients. To accomplish this, however, requires frequent intraocular injections and follow-up, costly in time and money to the patient and the health-care system. In the near future, it is likely that newer strategies and newer drugs will make the treatment of AMD easier, more effective, and more affordable.
Bryan
Richard G
RG
Warren Alpert Medical School, Brown University, Providence, RI, USA. rgbryan@alumni.duke.edu
D000375:Aging / Q000502:physiology*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004032:Diet; D019587:Dietary Supplements; D006801:Humans; D008028:Light Coagulation; D008268:Macular Degeneration / Q000503:physiopathology* / Q000628:therapy*; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab